COVID-19 mRNA BNT162b2 vaccine safety and B-cell and T-cell reactogenicity among children with a history of paediatric multisystem inflammatory syndrome temporally associated with COVID-19 (PIMS-TS) - preliminary study

To assess the safety of Pfizer-BioNTech COVID-19 mRNA BNT162b2 vaccine (Comirnaty®) among patients with the anamnesis of paediatric inflammatory syndrome temporally associated with COVID-19 (PIMS-TS), we conducted a prospective cohort study of 21 patients with history of PIMS (PIMS group, median age...

Descripción completa

Detalles Bibliográficos
Autores principales: Ludwikowska, Kamila M., Popiel, Aneta, Matkowska-Kocjan, Agnieszka, Olbromski, Mateusz J., Biela, Mateusz, Wójcik, Marta, Szenborn, Filip, Wielgos, Katarzyna, Pielka-Markiewicz, Ewa, Zaryczański, Janusz, Kursa, Miron B., Szenborn, Leszek
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier Ltd. 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9977623/
https://www.ncbi.nlm.nih.gov/pubmed/36870876
http://dx.doi.org/10.1016/j.vaccine.2023.02.072

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9977623/
https://www.ncbi.nlm.nih.gov/pubmed/36870876
http://dx.doi.org/10.1016/j.vaccine.2023.02.072

Ejemplares similares